The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients.
biomarkers
gut microbiota
immune checkpoint inhibitors
immunotherapy
melanoma
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
25 Sep 2020
25 Sep 2020
Historique:
received:
17
08
2020
revised:
17
09
2020
accepted:
18
09
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
1
10
2020
Statut:
epublish
Résumé
There are various melanoma treatment strategies that are based on immunological responses, among which immune checkpoint inhibitors (ICI) are relatively novel form. Nowadays, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) antibodies represent a standard treatment for metastatic melanoma. Although there are remarkable curative effects in responders to ICI therapy, up to 70% of melanoma patients show resistance to this treatment. This low response rate is caused by innate as well as acquired resistance, and some aspects of treatment resistance are still unknown. Growing evidence shows that gut microbiota and bacterial metabolites, such as short-chain fatty acids (SCFAs), affect the efficacy of immunotherapy. Various bacterial species have been indicated as potential biomarkers of anti-PD-1 or anti-CTLA-4 therapy efficacy in melanoma, next to biomarkers related to molecular and genetic tumor characteristics or the host immunological response, which are detected in patients' blood. Here, we review the current status of biomarkers of response to ICI melanoma therapies, their pre-treatment predictive values, and their utility as on-treatment monitoring tools in order to select a relevant personalized therapy on the basis of probability of the best clinical outcome.
Identifiants
pubmed: 32992737
pii: life10100219
doi: 10.3390/life10100219
pmc: PMC7600343
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Narodowym Centrum Nauki
ID : 2017/25/B/NZ5/01949
Références
J Immunol. 2011 Feb 15;186(4):2219-28
pubmed: 21242526
J Eur Acad Dermatol Venereol. 2018 Jun;32(6):972-977
pubmed: 29024038
Eur J Immunol. 2013 May;43(5):1274-85
pubmed: 23400950
Clin Cancer Res. 2017 Sep 1;23(17):5024-5033
pubmed: 28512174
Oncotarget. 2017 Mar 28;8(13):21539-21553
pubmed: 28423487
Hum Immunol. 2017 Feb;78(2):113-119
pubmed: 27939507
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Surg Clin North Am. 2020 Feb;100(1):175-188
pubmed: 31753111
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Br J Cancer. 2019 Jan;120(1):6-15
pubmed: 30413827
Genome Med. 2019 Oct 9;11(1):61
pubmed: 31597568
Cancer Res. 1991 Jan 15;51(2):729-36
pubmed: 1985791
J Immunother Cancer. 2018 Jul 16;6(1):74
pubmed: 30012216
J Exp Med. 2019 Apr 1;216(4):982-1000
pubmed: 30872362
Pigment Cell Melanoma Res. 2015 May;28(3):245-53
pubmed: 25477049
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Cancer Lett. 2019 Apr 10;447:41-47
pubmed: 30684593
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
JAMA Netw Open. 2020 Apr 1;3(4):e202895
pubmed: 32297948
Expert Opin Drug Metab Toxicol. 2016;12(1):31-40
pubmed: 26569070
Nat Rev Clin Oncol. 2018 Oct;15(10):639-650
pubmed: 30050094
Eur J Clin Invest. 2018 Nov;48 Suppl 2:e12943
pubmed: 29682724
J Extracell Vesicles. 2020 Jan 7;9(1):1710899
pubmed: 32002173
Cancer Immunol Immunother. 2014 Jul;63(7):675-83
pubmed: 24695951
Eur J Cancer. 2016 May;59:152-159
pubmed: 27039170
Clin Biochem. 2004 Jul;37(7):512-8
pubmed: 15234232
Nat Rev Immunol. 2011 Nov 11;11(12):823-36
pubmed: 22076556
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496
pubmed: 27185375
Br J Cancer. 2018 Aug;119(3):339-346
pubmed: 29950611
Scand J Immunol. 2017 Nov;86(5):361-367
pubmed: 28930374
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Clin Exp Immunol. 2019 Jul;197(1):74-82
pubmed: 30821848
Clin Lung Cancer. 2018 Sep;19(5):410-417.e1
pubmed: 29859759
Cytokine. 2011 Nov;56(2):231-8
pubmed: 21733718
Cell Res. 2015 Feb;25(2):208-24
pubmed: 25582080
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
J Cancer Res Clin Oncol. 2019 Feb;145(2):303-312
pubmed: 30267213
J Clin Oncol. 2013 Nov 20;31(33):4252-9
pubmed: 24127443
Clin Cancer Res. 2015 Feb 15;21(4):712-20
pubmed: 25524312
PLoS One. 2014 Feb 03;9(2):e87705
pubmed: 24498358
Cancer. 2020 Jan 1;126(1):76-85
pubmed: 31584709
J Dermatol Sci. 2017 Apr;86(1):71-73
pubmed: 28069323
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Front Physiol. 2018 Feb 20;9:113
pubmed: 29515456
Cancer Immunol Res. 2016 Apr;4(4):345-53
pubmed: 26873574
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Cancer Immunol Immunother. 2019 Jan;68(1):97-107
pubmed: 30311027
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
Contemp Oncol (Pozn). 2017;21(1):1-5
pubmed: 28435391
J Clin Oncol. 2016 Dec;34(34):4102-4109
pubmed: 27863197
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
Cancer Immunol Immunother. 2019 Mar;68(3):407-420
pubmed: 30564890
BMC Cancer. 2018 Nov 12;18(1):1086
pubmed: 30415640
Cancer Immunol Res. 2017 Jun;5(6):480-492
pubmed: 28522460
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Cancer Immunol Immunother. 2014 May;63(5):449-58
pubmed: 24609989
Cancer Med. 2018 Mar;7(3):690-697
pubmed: 29468834
Ann Oncol. 2017 Jun 1;28(6):1368-1379
pubmed: 28368458
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Transl Med. 2019 Sep 5;17(1):303
pubmed: 31488153
Br J Cancer. 2012 Jul 24;107(3):422-8
pubmed: 22782342
JAMA Netw Open. 2020 Mar 2;3(3):e201611
pubmed: 32211869
Cancer Invest. 2019;37(6):265-274
pubmed: 31304800
Biochem J. 2017 May 16;474(11):1823-1836
pubmed: 28512250
Immunotherapy. 2019 Apr;11(5):429-441
pubmed: 30698054
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Lancet Infect Dis. 2015 Oct;15(10):1211-1219
pubmed: 26311042
Nat Commun. 2016 Jan 29;7:10582
pubmed: 26822383
Nat Commun. 2020 May 1;11(1):2168
pubmed: 32358520
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Curr Opin Oncol. 2017 Nov;29(6):484-492
pubmed: 28914644
Immunotargets Ther. 2018 Jun 07;7:35-49
pubmed: 29922629
Lung Cancer. 2017 Feb;104:1-6
pubmed: 28212990
Front Immunol. 2018 Aug 15;9:1830
pubmed: 30158926
Mol Cancer. 2019 Oct 23;18(1):146
pubmed: 31647023
Lung Cancer. 2017 Oct;112:75-80
pubmed: 29191604
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Elife. 2019 Nov 15;8:
pubmed: 31729316
Nat Rev Cancer. 2004 Jan;4(1):11-22
pubmed: 14708024
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Int J Cancer. 2015 May 15;136(10):2352-60
pubmed: 25353097
N Engl J Med. 2012 Mar 8;366(10):925-31
pubmed: 22397654
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Clin Cancer Res. 2015 Dec 15;21(24):5453-9
pubmed: 26289067
Adv Exp Med Biol. 2019;1151:79-90
pubmed: 31140107
Br J Dermatol. 2016 Jan;174(1):146-51
pubmed: 26343230
JAMA Oncol. 2018 May 1;4(5):717-721
pubmed: 29423503
J Clin Oncol. 2013 Nov 10;31(32):e439-42
pubmed: 24043743
Br J Dermatol. 2018 Jul;179(1):213-215
pubmed: 29405254
Cancer Immunol Immunother. 2005 Apr;54(4):307-14
pubmed: 15599732
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021886
J Leukoc Biol. 2017 Sep;102(3):727-740
pubmed: 28546500
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Contemp Oncol (Pozn). 2018 Mar;22(1A):61-67
pubmed: 29628796
Immunotherapy. 2016 Sep;8(9):1033-44
pubmed: 27485076
Science. 2013 Nov 22;342(6161):971-6
pubmed: 24264990
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
J Clin Oncol. 2015 Apr 20;33(12):1389-96
pubmed: 25779565
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Biomarkers. 2008 Feb;13(1):1-26
pubmed: 17906988
Clin Cancer Res. 2016 Jun 15;22(12):2908-18
pubmed: 26787752
Oncotarget. 2016 Nov 22;7(47):77404-77415
pubmed: 27764805
Eur J Immunol. 1999 Nov;29(11):3596-602
pubmed: 10556814
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Cancers (Basel). 2020 Feb 18;12(2):
pubmed: 32085544
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Front Oncol. 2020 Feb 11;10:91
pubmed: 32117745
J Biol Chem. 2012 May 4;287(19):15874-85
pubmed: 22396543
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
Br J Cancer. 2016 Feb 2;114(3):256-61
pubmed: 26794281
Neoplasia. 2017 Oct;19(10):848-855
pubmed: 28923537
Br J Cancer. 2003 Feb 10;88(3):424-31
pubmed: 12569387
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2019 Mar 1;25(5):1557-1563
pubmed: 30409824
Cancer Sci. 2017 May;108(5):1022-1031
pubmed: 28266140
Oncotarget. 2015 Dec 8;6(39):42008-18
pubmed: 26524482
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Cancer Immunol Immunother. 2014 Mar;63(3):247-57
pubmed: 24357148
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
J Hematol Oncol. 2018 Mar 27;11(1):47
pubmed: 29580257
Front Oncol. 2014 May 16;4:110
pubmed: 24904825
Br J Cancer. 2015 Jun 9;112(12):1904-10
pubmed: 26010413
Breast Cancer Res. 2010;12(4):R48
pubmed: 20626886
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936
Clin Cancer Res. 2018 Dec 15;24(24):6236-6247
pubmed: 30131384